Inhibikase Therapeutics (IKT) Receivables (2021 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly Receivables of $79604.0 for Q2 2023, up 1114.96% year-over-year from $6552.0 in Q2 2022, and up 23.38% quarter-over-quarter from $64521.0 in Q1 2023.
Inhibikase Therapeutics (IKT) Receivables (2021 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Receivables for 3 consecutive years, with $79604.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Receivables rose 1114.96% year-over-year to $79604.0; the TTM figure through Jun 2023 stood at $79604.0 (up 1114.96% YoY), while the FY2022 annual figure was $39881.0, down 63.79% from the prior year.
- Receivables rose to $79604.0 in Q2 2023 per IKT's latest filing, from $64521.0 in the prior quarter.
- Across five years, Receivables topped out at $586581.0 in Q2 2021 and bottomed at $6552.0 in Q2 2022.
- Historically, Receivables has averaged $149935.4 across 3 years, with a median of $72062.5 in 2023.
- Annual changes were most pronounced in 2022 — Receivables sank 98.88% — and 2023, when it soared 1114.96%.
- Inhibikase Therapeutics' Receivables stood at $110141.0 in 2021, then tumbled by 63.79% to $39881.0 in 2022, then surged by 99.6% to $79604.0 in 2023.
- Business Quant data shows IKT's Receivables at $79604.0 in Q2 2023, $64521.0 in Q1 2023, and $39881.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 79,604.00 |
| Mar 31, 2023 | 64,521.00 |
| Dec 31, 2022 | 39,881.00 |
| Sep 30, 2022 | 13,842.00 |
| Jun 30, 2022 | 6,552.00 |
| Mar 31, 2022 | 47,976.00 |
| Dec 31, 2021 | 110,141.00 |
| Sep 30, 2021 | 217,482.00 |
| Jun 30, 2021 | 586,581.00 |
| Mar 31, 2021 | 332,774.00 |